Compare · SYK vs TELA
SYK vs TELA
Side-by-side comparison of Stryker Corporation (SYK) and TELA Bio Inc. (TELA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYK and TELA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 4035.0x TELA ($31.4M).
- TELA has been more active in the news (14 items in the past 4 weeks vs 9 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 2 for TELA).
- Company
- Stryker Corporation
- TELA Bio Inc.
- Price
- -
- -
- Market cap
- $126.81B
- $31.4M
- 1M return
- -4.15%
- -
- 1Y return
- -15.83%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 9
- 14
- Recent ratings
- 25
- 2
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
TELA Bio Inc.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation
Latest TELA
- Chief Executive Officer Getz Heather C bought $8,311 worth of shares (12,500 units at $0.66), increasing direct ownership by 2% to 532,500 units (SEC Form 4)
- Chief Executive Officer Getz Heather C bought $10,467 worth of shares (15,000 units at $0.70), increasing direct ownership by 3% to 520,000 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.
- Amendment: TELA Bio Inc. filed SEC Form 8-K: Leadership Update
- SEC Form S-8 filed by TELA Bio Inc.
- SEC Form 10-Q filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TELA Bio Reports Second Quarter 2026 Financial Results
- Chief Executive Officer Getz Heather C was granted 500,000 shares, increasing direct ownership by 10,000% to 505,000 units (SEC Form 4)
- New insider Getz Heather C claimed ownership of 5,000 shares (SEC Form 3)